Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS

Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS

Copyright © 2023 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 250(2023) vom: 15. Mai, Seite 109324
1. Verfasser: LaFon, David C (VerfasserIn)
Weitere Verfasser: Woo, Han, Fedarko, Neal, Azar, Antoine, Hill, Harry, Tebo, Anne E, Martins, Thomas B, Han, MeiLan K, Krishnan, Jerry A, Ortega, Victor E, Barjaktarevic, Igor, Kaner, Robert J, Hastie, Annette, O'Neal, Wanda K, Couper, David, Woodruff, Prescott G, Curtis, Jeffrey L, Hansel, Nadia N, Nahm, Moon H, Dransfield, Mark T, Putcha, Nirupama, SPIROMICS investigators
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Antibodies Immunity Immunoglobulin G Opsonization Streptococcus pneumoniae Antibodies, Bacterial Pneumococcal Vaccines
LEADER 01000caa a22002652c 4500
001 NLM355351757
003 DE-627
005 20250304152746.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2023.109324  |2 doi 
028 5 2 |a pubmed25n1184.xml 
035 |a (DE-627)NLM355351757 
035 |a (NLM)37030524 
035 |a (PII)S1521-6616(23)00103-1 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a LaFon, David C  |e verfasserin  |4 aut 
245 1 0 |a Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 28.04.2023 
500 |a Date Revised 23.09.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2023 Elsevier Inc. All rights reserved. 
520 |a While hypogammaglobulinemia is associated with COPD exacerbations, it is unknown whether frequent exacerbators have specific defects in antibody production/function. We hypothesized that reduced quantity/function of serum pneumococcal antibodies correlate with exacerbation risk in the SPIROMICS cohort. We measured total pneumococcal IgG in n = 764 previously vaccinated participants with COPD. In a propensity-matched subset of n = 200 with vaccination within five years (n = 50 without exacerbations in the previous year; n = 75 with one, n = 75 with ≥2), we measured pneumococcal IgG for 23 individual serotypes, and pneumococcal antibody function for 4 serotypes. Higher total pneumococcal IgG, serotype-specific IgG (17/23 serotypes), and antibody function (3/4 serotypes) were independently associated with fewer prior exacerbations. Higher pneumococcal IgG (5/23 serotypes) predicted lower exacerbation risk in the following year. Pneumococcal antibodies are inversely associated with exacerbations, supporting the presence of immune defects in frequent exacerbators. With further study, pneumococcal antibodies may be useful biomarkers for immune dysfunction in COPD 
650 4 |a Journal Article 
650 4 |a Research Support, N.I.H., Extramural 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Antibodies 
650 4 |a Immunity 
650 4 |a Immunoglobulin G 
650 4 |a Opsonization 
650 4 |a Streptococcus pneumoniae 
650 7 |a Immunoglobulin G  |2 NLM 
650 7 |a Antibodies, Bacterial  |2 NLM 
650 7 |a Pneumococcal Vaccines  |2 NLM 
700 1 |a Woo, Han  |e verfasserin  |4 aut 
700 1 |a Fedarko, Neal  |e verfasserin  |4 aut 
700 1 |a Azar, Antoine  |e verfasserin  |4 aut 
700 1 |a Hill, Harry  |e verfasserin  |4 aut 
700 1 |a Tebo, Anne E  |e verfasserin  |4 aut 
700 1 |a Martins, Thomas B  |e verfasserin  |4 aut 
700 1 |a Han, MeiLan K  |e verfasserin  |4 aut 
700 1 |a Krishnan, Jerry A  |e verfasserin  |4 aut 
700 1 |a Ortega, Victor E  |e verfasserin  |4 aut 
700 1 |a Barjaktarevic, Igor  |e verfasserin  |4 aut 
700 1 |a Kaner, Robert J  |e verfasserin  |4 aut 
700 1 |a Hastie, Annette  |e verfasserin  |4 aut 
700 1 |a O'Neal, Wanda K  |e verfasserin  |4 aut 
700 1 |a Couper, David  |e verfasserin  |4 aut 
700 1 |a Woodruff, Prescott G  |e verfasserin  |4 aut 
700 1 |a Curtis, Jeffrey L  |e verfasserin  |4 aut 
700 1 |a Hansel, Nadia N  |e verfasserin  |4 aut 
700 1 |a Nahm, Moon H  |e verfasserin  |4 aut 
700 1 |a Dransfield, Mark T  |e verfasserin  |4 aut 
700 1 |a Putcha, Nirupama  |e verfasserin  |4 aut 
700 0 |a SPIROMICS investigators  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 250(2023) vom: 15. Mai, Seite 109324  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:250  |g year:2023  |g day:15  |g month:05  |g pages:109324 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2023.109324  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 250  |j 2023  |b 15  |c 05  |h 109324